Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNU6-146P** refers to a human pseudogene derived from the U6 small nuclear RNA (snRNA) gene family. U6 snRNAs are critical components of the spliceosome, forming part of the core machinery required for the excision of introns from pre-mRNA during pre-mRNA splicing[1][2]. However, as a *pseudogene*, RNU6-146P does not produce a functional product and is generally considered transcriptionally inactive. Pseudogenes such as RNU6-146P often arise by gene duplication or retrotransposition events and retain high sequence similarity to their functional counterpart, but they typically contain disabling mutations that prevent them from performing their original biological function[3]. The existence of multiple U6-related pseudogenes is common in the human genome and other vertebrates, reflecting the evolutionary importance of functional U6 and the frequent genomic rearrangement of small non-coding RNA genes[2][3]. There is no evidence that RNU6-146P serves as a therapeutic target, biomarker, or has any clinical pharmacology or safety concerns associated with it.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 146, pseudogene (RNU6-146P).